Ngā hua rapu - Adewoye, Adeboye

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study mā Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis— mā Nolan, Vikki G., Adewoye, Adeboye, Baldwin, Clinton, Wang, Ling, Ma, Qianli, Wyszynski, Diego F., Farrell, John J., Sebastiani, Paola, Farrer, Lindsay A., Steinberg, Martin H.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer mā De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70 mā Adewoye, Adeboye H., Klings, Elizabeth S., Farber, Harrison W., Palaima, Elizabeth, Bausero, Maria A., McMahon, Lillian, Odhiambo, Adam, Surinder, Safaya, Yoder, Mark, Steinberg, Martin H., Asea, Alexzander

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies mā Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials mā Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

A network model to predict the risk of death in sickle cell disease mā Sebastiani, Paola, Nolan, Vikki G., Baldwin, Clinton T., Abad-Grau, Maria M., Wang, Ling, Adewoye, Adeboye H., McMahon, Lillian C., Farrer, Lindsay A., Taylor, James G., Kato, Gregory J., Gladwin, Mark T., Steinberg, Martin H.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro... mā Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa